|
1
|
Mirabello L, Troisi RJ and Savage SA:
International osteosarcoma incidence patterns in children and
adolescents, middle ages and elderly persons. Int J Cancer.
125:229–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the Surveillance, Epidemiology, and End Results Program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang Y, Han L, He Z, Li X, Yang S, Yang J,
Zhang Y, Li D, Yang Y and Yang Z: Advances in limb salvage
treatment of osteosarcoma. J Bone Oncol. 10:36–40. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
McGuire J, Utset-Ward TJ, Reed DR and
Lynch CC: Re-calculating! Navigating through the osteosarcoma
treatment roadblock. Pharmacol Res. 117:54–64. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment-where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Friebele JC, Peck J, Pan X, Abdel-Rasoul M
and Mayerson JL: Osteosarcoma: A meta-analysis and review of the
literature. Am J Orthop (Belle Mead NJ). 44:547–553.
2015.PubMed/NCBI
|
|
7
|
Bacci G and Lari S: Adjuvant and
neoadjuvant chemotherapy in osteosarcoma. Chir Organi Mov.
86:253–268. 2001.PubMed/NCBI
|
|
8
|
Carrle D and Bielack SS: Current
strategies of chemotherapy in osteosarcoma. Int Orthop. 30:445–451.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ferrari S and Serra M: An update on
chemotherapy for osteosarcoma. Expert Opin Pharmacother.
16:2727–2736. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Anninga JK, Gelderblom H, Fiocco M, Kroep
JR, Taminiau AH, Hogendoorn PC and Egeler RM: Chemotherapeutic
adjuvant treatment for osteosarcoma: Where do we stand? Eur J
Cancer. 47:2431–2445. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bacci G, Ferrari S, Longhi A, Picci P,
Mercuri M, Alvegard TA, Saeter G, Donati D, Manfrini M, Lari S, et
al: High dose ifosfamide in combination with high dose
methotrexate, adriamycin and cisplatin in the neoadjuvant treatment
of extremity osteosarcoma: Preliminary results of an Italian
Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother.
14:198–206. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bodmer N, Walters DK and Fuchs B:
Pemetrexed, a multitargeted antifolate drug, demonstrates lower
efficacy in comparison to methotrexate against osteosarcoma cell
lines. Pediatr Blood Cancer. 50:905–908. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Duffaud F, Egerer G, Ferrari S, Rassam H,
Boecker U and Bui-Nguyen B: A phase II trial of second-line
pemetrexed in adults with advanced/metastatic osteosarcoma. Eur J
Cancer. 48:564–570. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Machak GN, Tkachev SI, Solovyev YN,
Sinyukov PA, Ivanov SM, Kochergina NV, Ryjkov AD, Tepliakov VV,
Bokhian BY and Glebovskaya VV: Neoadjuvant chemotherapy and local
radiotherapy for high-grade osteosarcoma of the extremities. Mayo
Clin Proc. 78:147–155. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chou AJ and Gorlick R: Chemotherapy
resistance in osteosarcoma: Current challenges and future
directions. Expert Rev Anticancer Ther. 6:1075–1085. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li S, Sun W, Wang H, Zuo D, Hua Y and Cai
Z: Research progress on the multidrug resistance mechanisms of
osteosarcoma chemotherapy and reversal. Tumour Biol. 36:1329–1338.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ozaki T, Flege S, Kevric M, Lindner N,
Maas R, Delling G, Schwarz R, von Hochstetter AR, Salzer-Kuntschik
M, Berdel WE, et al: Osteosarcoma of the pelvis: Experience of the
Cooperative Osteosarcoma Study Group. J Clin Oncol. 21:334–341.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ozaki T, Flege S, Liljenqvist U, Hillmann
A, Delling G, Salzer-Kuntschik M, Jürgens H, Kotz R, Winkelmann W
and Bielack SS: Osteosarcoma of the spine: Experience of the
Cooperative Osteosarcoma Study Group. Cancer. 94:1069–1077. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mohamad O, Imai R, Kamada T, Nitta Y and
Araki N; Working Group for Bone and Soft Tissue Sarcoma, : Carbon
ion radiotherapy for inoperable pediatric osteosarcoma. Oncotarget.
9:22976–22985. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Matsunobu A, Imai R, Kamada T, Imaizumi T,
Tsuji H, Tsujii H, Shioyama Y, Honda H and Tatezaki S; Working
Group for Bone and Soft Tissue Sarcomas, : Impact of carbon ion
radiotherapy for unresectable osteosarcoma of the trunk. Cancer.
118:4555–4563. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Delaney G, Jacob S, Featherstone C and
Barton M: The role of radiotherapy in cancer treatment: Estimating
optimal utilization from a review of evidence-based clinical
guidelines. Cancer. 104:1129–1137. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schwarz R, Bruland O, Cassoni A, Schomberg
P and Bielack S: The role of radiotherapy in oseosarcoma. Cancer
Treat Res. 152:147–164. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu D, Chen K, Bai Y, Zhu X, Chen Z, Wang
C, Zhao Y and Li M: Screening of diagnostic markers for
osteosarcoma. Mol Med Rep. 10:2415–2420. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Engert F, Kovac M, Baumhoer D, Nathrath M
and Fulda S: Osteosarcoma cells with genetic signatures of BRCAness
are susceptible to the PARP inhibitor talazoparib alone or in
combination with chemotherapeutics. Oncotarget. 8:48794–48806.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li B and Ye Z: Epigenetic alterations in
osteosarcoma: Promising targets. Mol Biol Rep. 41:3303–3315. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Turner N, Tutt A and Ashworth A: Hallmarks
of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 4:814–819. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lord CJ and Ashworth A: BRCAness
revisited. Nat Rev Cancer. 16:110–120. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee JA, Paik EK, Seo J, Kim DH, Lim JS,
Yoo JY and Kim MS: Radiotherapy and gemcitabine-docetaxel
chemotherapy in children and adolescents with unresectable
recurrent or refractory osteosarcoma. Jpn J Clin Oncol. 46:138–143.
2016.PubMed/NCBI
|
|
29
|
Dinçbaş FO, Koca S, Mandel NM, Hiz M,
Dervişoğlu S, Seçmezacar H, Oksüz DC, Ceylaner B and Uzel B: The
role of preoperative radiotherapy in nonmetastatic high-grade
osteosarcoma of the extremities for limb-sparing surgery. Int J
Radiat Oncol Biol Phys. 62:820–828. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Marín A, Martín M, Liñán O, Alvarenga F,
López M, Fernández L, Büchser D and Cerezo L: Bystander effects and
radiotherapy. Rep Pract Oncol Radiother. 20:12–21. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lewanski CR and Gullick WJ: Radiotherapy
and cellular signalling. Lancet Oncol. 2:366–370. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang D and Lippard SJ: Cellular processing
of platinum anticancer drugs. Nat Rev Drug Discov. 4:307–320. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Muggia F: Platinum compounds 30 years
after the introduction of cisplatin: Implications for the treatment
of ovarian cancer. Gynecol Oncol. 112:275–281. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Marcu L, van Doorn T and Olver I:
Cisplatin and radiotherapy in the treatment of locally advanced
head and neck cancer-a review of their cooperation. Acta Oncol.
42:315–325. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Petrelli F, De Stefani A, Raspagliesi F,
Lorusso D and Barni S: Radiotherapy with concurrent cisplatin-based
doublet or weekly cisplatin for cervical cancer: A systematic
review and meta-analysis. Gynecol Oncol. 134:166–171. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jacinto JK, Co J, Mejia MB and Regala EE:
The evidence on effectiveness of weekly vs triweekly cisplatin
concurrent with radiotherapy in locally advanced head and neck
squamous cell carcinoma (HNSCC): A systematic review and
meta-analysis. Br J Radiol. 90:201704422017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhong Q, Chen CF, Li S, Chen Y, Wang CC,
Xiao J, Chen PL, Sharp ZD and Lee WH: Association of BRCA1 with the
hRad50-hMre11-p95 complex and the DNA damage response. Science.
285:747–750. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Caestecker KW and Van de Walle GR: The
role of BRCA1 in DNA double-strand repair: Past and present. Exp
Cell Res. 319:575–587. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang J and Powell SN: The role of the
BRCA1 tumor suppressor in DNA double-strand break repair. Mol
Cancer Res. 3:531–539. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Song H, Cicek MS, Dicks E, Harrington P,
Ramus SJ, Cunningham JM, Fridley BL, Tyrer JP, Alsop J,
Jimenez-Linan M, et al: The contribution of deleterious germline
mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian
cancer in the population. Hum Mol Genet. 23:4703–4709. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ramus SJ and Gayther SA: The contribution
of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol. 3:138–150. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ratanaphan A: A DNA repair BRCA1 estrogen
receptor and targeted therapy in breast cancer. Int J Mol Sci.
13:14898–14916. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chechlinska M and Nowak R: The sensitivity
of BRCA1 mutation carriers to ionising radiation: Questions of
methodology. Breast Cancer Res Treat. 115:4332009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shi M, Ma F, Liu J, Xing H, Zhu H, Yu J
and Yang M: A functional BRCA1 coding sequence genetic variant
contributes to prognosis of triple-negative breast cancer,
especially after radiotherapy. Breast Cancer Res Treat.
166:109–116. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hallam S, Govindarajulu S, Huckett B and
Bahl A: BRCA1/2 mutation-associated breast cancer, wide local
excision and radiotherapy or unilateral mastectomy: A systematic
review. Clin Oncol (R Coll Radiol). 27:527–535. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Flórez MM, Fêo HB, da Silva GN, Yamatogi
RS, Aguiar AJ, Araújo JP Jr and Rocha NS: Cell cycle kinetics,
apoptosis rates and gene expressions of MDR-1, TP53, BCL-2 and BAX
in transmissible venereal tumour cells and their association with
therapy response. Vet Comp Oncol. 15:793–807. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zheng Q, Wang B, Gao J, Xin N, Wang W,
Song X, Shao Y and Zhao C: CD155 knockdown promotes apoptosis via
AKT/Bcl-2/Bax in colon cancer cells. J Cell Mol Med. 22:131–140.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fokkema E, De Vries EG, Groen HJ, Meijer C
and Timens W: Expression of apoptosis-related proteins and
morphological changes in a rat tumor model of human small cell lung
cancer prior to and after treatment with radiotherapy, carboplatin,
or combined treatment. Virchows Arch. 442:349–355. 2003.PubMed/NCBI
|
|
50
|
Miyazaki T, Kato H, Faried A, Sohda M,
Nakajima M, Fukai Y, Masuda N, Manda R, Fukuchi M, Ojima H, et al:
Predictors of response to chemo-radiotherapy and radiotherapy for
esophageal squamous cell carcinoma. Anticancer Res. 25:2749–2755.
2005.PubMed/NCBI
|
|
51
|
Jeong SH, Jung JH, Han JH, Kim JH, Choi
YW, Lee HW, Kang SY, Hwang YH, Ahn MS, Choi JH, et al: Expression
of Bcl-2 predicts outcome in locally advanced non-small cell lung
cancer patients treated with cisplatin-based concurrent
chemoradiotherapy. Lung Cancer. 68:288–294. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hassan C, Afshinnekoo E, Li S, Wu S and
Mason CE: Genetic and epigenetic heterogeneity and the impact on
cancer relapse. Exp Hematol. 54:26–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Gentric G, Mieulet V and Mechta-Grigoriou
F: Heterogeneity in cancer metabolism: New concepts in an old
field. Antioxid Redox Signal. 26:462–485. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Dagogo-Jack I and Shaw AT: Tumour
heterogeneity and resistance to cancer therapies. Nat Rev Clin
Oncol. 15:81–94. 2018. View Article : Google Scholar : PubMed/NCBI
|
